56.09
1.67 (3.07%)
| Previous Close | 54.42 |
| Open | 54.50 |
| Volume | 567,345 |
| Avg. Volume (3M) | 1,229,446 |
| Market Cap | 4,947,276,800 |
| Price / Sales | 975.15 |
| Price / Book | 5.03 |
| 52 Weeks Range | |
| Earnings Date | 7 Aug 2026 |
| Operating Margin (TTM) | -81,161.54% |
| Diluted EPS (TTM) | -1.50 |
| Quarterly Revenue Growth (YOY) | -90.20% |
| Total Debt/Equity (MRQ) | 0.15% |
| Current Ratio (MRQ) | 30.97 |
| Operating Cash Flow (TTM) | -81.98 M |
| Levered Free Cash Flow (TTM) | -57.18 M |
| Return on Assets (TTM) | -12.85% |
| Return on Equity (TTM) | -16.58% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | CG Oncology, Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 2.0 |
| Insider Activity | NA |
| Price Volatility | 2.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -0.5 |
| Average | 0.88 |
|
CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The company's candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 1.17% |
| % Held by Institutions | 105.34% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Seven Fleet Capital Management Lp | 31 Mar 2026 | 1,515,151 |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |